Top Markets
#1 EXOD EXOD +56.80%
#2 Arowana Arowana +8.48%
#3 Harmony Harmony +7.27%
#4 Fake World Assets Fake World Assets +6.48%
#5 Cysic Cysic +5.83%
#6 Orochi Network Orochi Network +3.92%
#7 Dual Dual +3.59%
#8 Fabric Protocol Fabric Protocol +3.54%
#9 Figure Heloc Figure Heloc +3.49%
#10 TAGGER TAGGER +3.35%
Coin of the day
EXOD EXOD
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Pascal Biosciences Inc. Pascal Biosciences Inc.

Pascal Biosciences Inc.

PSCBF
Rang in aandelen #37975
Pascal Biosciences Inc. is an innovative biopharmaceutical firm dedicated to... Pascal Biosciences Inc. is an innovative biopharmaceutical firm dedicated to discovering and advancing therapeutic solutions for oncology and bolstering immune system function. The company's robust pipeline includes several key candidates: PAS-403, a potent mitosis inhibitor designed to impede cancerous cell division, specifically targeting glioblastoma and secondary brain tumors; and PAS-393, an immunomodulatory cannabinoid developed to enhance the immune system's recognition of tumor cells when utilized alongside checkpoint inhibitor therapy. Furthermore, Pascal is progressing a specialized antibody therapy aimed at B-cells, intended for conditions like acute lymphoblastic leukemia and various B-cell lymphomas. The company is also investigating cannabinoid-derived products as potential treatments for COVID-19. To support its research, Pascal Biosciences maintains an exclusive licensing agreement with the University of Washington for a cannabinoid-based therapeutic against glioblastoma multiforme and brain metastases. It also benefits from a collaborative research partnership with SoRSE Technology Corporation, focused on advancing PAS-393 toward clinical trials. Founded in 2011, the company operates from its headquarters in Seattle, Washington.
Aandeelprijs
$0.1
Laatst gesynchroniseerd: 2024-06-18
Marktkapitalisatie
$1.31M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Pascal Biosciences Inc. (PSCBF)

Categorie

Healthcare
P/S-ratio voor Pascal Biosciences Inc. (PSCBF)
P/S-ratio op August 2026 TTM: 8.78
Volgens de meest recente financiële rapporten en aandelenkoers van Pascal Biosciences Inc. is de huidige P/S-ratio (TTM) 8.78. Eind 2022 had het bedrijf een P/S-ratio van 0.00.
P/S-ratiohistoriek voor Pascal Biosciences Inc. van 2019 tot 2026
P/S-ratio aan het einde van elk jaar
Jaar P/S-ratio Wijzigen
2026 (TTM) 8.78 268.74%
2023 2.38 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
P/S-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/S-ratio Verschil in P/S-ratio Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.88 12.59%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.30 17.40%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.98 -43.26%
BE